Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Relapsed or Refractory Waldenström Macroglobulinemia
NCT02677324Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in Waldenström macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started May 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02677324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677324.